Last edition
News about "Regeneron"
Alvotech Reaches Global Settlement on Eylea Biosimilar
The settlement enables Alvotech and its partners to launch the biosimilar from January 1, 2026 in the UK and Canada, from May 1, 2026 in the EEA and other markets outside the US, and in Japan from May 2026 for select indications, expanding to all approved indications from November 1, 2026.
Regeneron | 30/01/2026 | By News Bureau | 157
Phase 3 results show Dupixent significantly improved nasal symptoms and sinus health in patients aged six and above with allergic fungal rhinosinusitis, supporting its FDA priority review.
Regeneron | 10/11/2025 | By Dineshwori | 170
ModeX and Regeneron Partner to Develop Multispecific Antibodies
ModeX Therapeutics has entered into a research collaboration with Regeneron to develop multispecific antibodies capable of targeting multiple biological pathways within a single molecule. The partnership, valued at over USD 1 Billion, if multiple assets advance, aims to accelerate innovation across select therapeutic areas.
Regeneron | 30/10/2025 | By Dineshwori | 239
Alvotech and Advanz Pharma Secure European Approval for Eylea Biosimilar Mynzepli
Alvotech and its commercial partner Advanz Pharma have announced that the European Commission has granted marketing authorisation for Mynzepli (aflibercept), a biosimilar to Eylea, available in both pre-filled syringes and vials.
Regeneron | 22/08/2025 | By Dineshwori | 176
Zuellig Pharma Signs Exclusive Distribution Deal with Regeneron to Launch Libtayo
Regeneron is a biotechnology company that invents, develops and commercialises life-transforming medicines for people with serious diseases.
Regeneron | 28/08/2024 | By Aishwarya | 461
Regeneron's Covid treatment review extended by FDA
The U.S. FDA is broadening the survey date for Regeneron Pharmaceuticals' COVID-19 immune response mixed drink back by 90 days. The choice was made after information showed it might assist with forestalling disease.
Regeneron | 16/04/2022 | By Sudeep Soparkar | 513
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy